NCT05644717

Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD

Effects of Ertugliflozin on Liver Fat, Liver Fibrosis & Glycemic Control in Subjects With Type 2 Diabetes Mellitus (T2DM) & Non-Alcoholic Fatty Liver Disease /Non-Alcoholic Steatohepatitis

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 164 (estimated)
• Sponsor: Getz Pharma · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Open-label, prospective, single-arm, multicenter study to determine effects of Ertugliflozin on liver fat, liver fibrosis \& glycemic control in subjects with Type 2 Diabetes Mellitus (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH)

Conditions

• Liver Fat
• Liver Fibrosis
• Glycemic Control
• Body Weight Changes
• Waist Circumference
• Tolerance

Interventions

Type	Name	Description
DRUG	Ertugliflozin 5 mg, 15mg	Ertugliflozin 5/15mg once daily in addition to standard of care

Timeline

• Start date: 2023-03-01
• Primary completion: 2025-11-01
• Completion: 2025-12-01
• First posted: 2022-12-09
• Last updated: 2025-03-21

Locations

1 site across 1 country: Pakistan